Proteomics: Technologies and Global Markets
The global proteomic market was worth nearly $3.7 billion in 2011 and nearly $4.2 billion in 2012, and is forecast to grow at a compound annual growth rate (CAGR) of 16.1% during the next five years to reach nearly $8.9 billion in 2017.
- An overview of the global proteomics market, which covers: technologies, database and software markets, equipment markets, application markets and service markets.
- Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017.
- Discussion of trends and opportunities, top-selling products, key players, and a competitive outlook.
- Comprehensive company profiles across subsegments, such as protein chip providers, reagent providers, service providers, informatics and database providers, etc.
The study scope covers MS instruments, consumables, workflow products, planar arrays, bead arrays and LOAC. It also covers the research, drug discovery and development, diagnostics and applied end-user market segments. The main geographical markets—North America, Europe, Japan and Rest of World (ROW)—are included.
The MS market is covered by instrument type, MS consumables, product type and end-user markets. The biochip market is covered by biochip type and the-end user market for each type. The diagnostics market is covered in some detail, including by major platform (i.e., MS, biochips), by disease type and for cancer by indication.
This report provides the current market sizes for these segments, as well as their forecasted growth through 2017.
Technology status and market driving forces are discussed. Factors that influence each market are also discussed, including growth-driving forces, industry alliances and acquisitions, applications in diagnostics and drug discovery, customer needs and competitive trends.
Key industry acquisitions and strategic alliances are given for the three-year period from 2010 through 2012.
This report also examines the main patent trends within the industry and profiles 83 companies.
John Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with a nanotechnology/separations company. Bergin holds a B.S. degree in Chemistry, an M.S. degree in Biotechnology and a Master of Business Administration. John Bergin is a pseudonym of the author.
- Global DNA Sequencing: Research, Applied and Clinical Markets (BIO045G)
- Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets (BIO150C)
- Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing (BIO159A)
- Single-cell Omics: Emerging Technologies and Markets (BIO143B)
- The global market for proteomics is expected to increase from $6.7 billion in 2008 to an estimated $7.9 billion in 2009 and $19.4 billion in 2014, for a compound annual growth rate (CAGR) of 19.7%.
- Proteomics equipment was valued at $4.1 billion in 2008 and an estimated $4.8 billion in 2009. This is expected to increase to $13.0 billion in 2014, for a CAGR of 22%..
- Proteomics technologies were worth $1.3 billion in 2008 and an estimated $1.5 billion in 2009. This segment is expected to increase at a CAGR of 13.9% to reach $2.9 billion in 2014.
Proteomics is an emerging field that has developed in the wake of genomics. Its goal is to understand protein expression at the cellular level, and apply this information to scientific and medical problems. For example, compared to healthy cells, how does influenza virus infection affect the total protein output? Are any of the proteins expressed only in the infected cells suitable targets for new antiviral drugs? This approach also applies to cancerous cells, and cells from patients with degenerative diseases and many other conditions. New technologies like protein chips and capillary electrophoresis are emerging to serve proteomic studies, and more mature technologies like 2-D electrophoresis, mass spectroscopy, and nuclear magnetic resonance spectroscopy are being adapted for protein studies, and in some cases, for high throughput uses. Bioinformatics applications are constantly being developed to analyze the data produced by all of these technologies.
This BCC study examines how proteomics technologies have affected basic research and pharmaceutical research, and how they are likely to affect research in the near future. It also analyzes how proteomics technologies are developing, and examines new companies that are likely to make substantial contributions to the field. An important part of the report analyzes instruments that are vital to proteomics studies. Sales and spending projections through 2006 are included.